NEW YORK (AP) — Swedish drug company Meda has rebuffed an approach from generic drug maker Mylan which was looking to combine the two businesses.
Meda AB says talks between the two companies have stopped “without further actions.” It did not provide any details as to why its board turned down the proposal.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.